Sage Therapeutics Inc (NASDAQ:SAGE) — Market Cap & Net Worth
Market Cap & Net Worth: Sage Therapeutics Inc (SAGE)
Sage Therapeutics Inc (NASDAQ:SAGE) has a market capitalization of $544.94 Million ($544.94 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12079 globally and #2850 in its home market, demonstrating a -1.03% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sage Therapeutics Inc's stock price $8.68 by its total outstanding shares 62781400 (62.78 Million). Analyse cash efficiency ratio of Sage Therapeutics Inc to see how efficiently the company converts income to cash.
Sage Therapeutics Inc Market Cap History: 2015 to 2025
Sage Therapeutics Inc's market capitalization history from 2015 to 2025. Data shows change from $3.66 Billion to $544.94 Million (-15.82% CAGR).
Index Memberships
Sage Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.02% | #311 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1151 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.03% | #177 of 263 |
Weight: Sage Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sage Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sage Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
8.27x
Sage Therapeutics Inc's market cap is 8.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $6.01 Billion | $90.27 Million | -$372.88 Million | 66.62x | N/A |
| 2019 | $4.53 Billion | $6.87 Million | -$650.15 Million | 659.90x | N/A |
| 2020 | $5.43 Billion | $1.11 Billion | $606.07 Million | 4.87x | 8.96x |
| 2021 | $2.67 Billion | $6.31 Million | -$450.83 Million | 423.39x | N/A |
| 2022 | $2.39 Billion | $7.69 Million | -$503.27 Million | 311.54x | N/A |
| 2023 | $1.36 Billion | $86.45 Million | -$541.49 Million | 15.74x | N/A |
| 2024 | $340.90 Million | $41.24 Million | -$400.67 Million | 8.27x | N/A |
Competitor Companies of SAGE by Market Capitalization
Companies near Sage Therapeutics Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Sage Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Sage Therapeutics Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Sage Therapeutics Inc's market cap moved from $3.66 Billion to $ 544.94 Million, with a yearly change of -15.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $544.94 Million | +59.85% |
| 2024 | $340.90 Million | -74.94% |
| 2023 | $1.36 Billion | -43.18% |
| 2022 | $2.39 Billion | -10.34% |
| 2021 | $2.67 Billion | -50.83% |
| 2020 | $5.43 Billion | +19.84% |
| 2019 | $4.53 Billion | -24.64% |
| 2018 | $6.01 Billion | -41.84% |
| 2017 | $10.34 Billion | +222.58% |
| 2016 | $3.21 Billion | -12.42% |
| 2015 | $3.66 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Sage Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $544.94 Million USD |
| MoneyControl | $544.94 Million USD |
| MarketWatch | $544.94 Million USD |
| marketcap.company | $544.94 Million USD |
| Reuters | $544.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sage Therapeutics Inc
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric m… Read more